申请人:Yissum Research Development Company of the Hebrew University of Jerusalem
公开号:US06531636B1
公开(公告)日:2003-03-11
The present invention relates to a compound of the general formula (I) which is a non-hydrolysable analogue of endogenous cannabinoids, which are found to be more potent therapeutic agents as they are more stable, for example, to hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues of the invention have a therapeutic value. Therefore, pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of at least one compound of the invention may be prepared. Such compositions may be used as anti-inflammatory, anti-asthmatic, analgetic, hypotensive, antiemetic or anti-spasmodic compositions, and as compositions for treating and/or preventing glaucoma or migraine, or as compositions for relieving symptoms of multiple sclerosis and mood stimulating compositions.
本发明涉及一种通式(I)的化合物,它是内源性大麻素的非水解类似物,发现它们作为治疗剂更具有强效性,因为它们更稳定,例如更耐胃肠道水解裂解。本发明的大麻素类似物具有治疗价值。因此,可以制备包含本发明至少一种化合物的治疗有效量作为活性成分的药物组合物。这样的组合物可以用作抗炎、抗哮喘、镇痛、降压、止吐或抗痉挛组合物,以及用于治疗和/或预防青光眼或偏头痛的组合物,或用于缓解多发性硬化症状和情绪刺激组合物。